SAKAR Sakar Healthcare Q4 FY26 results (Jan–Mar 2026) and concall
Sakar Healthcare reported a strong Q4 and full-year FY26, driven by significant growth in its oncology division and improved operational efficiencies. Revenue, EBITDA, and PAT saw substantial year-on-year increases. The company is transitioning into a focused specialty oncology player with a robust pipeline of products and regulatory approvals, aiming for continued export-led growth and margin expansion in the coming years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 42.0%, net profit up 83.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 43 | 50 | 53 | 58 | 70 +63% | 71 +42% |
| EBITDA | 12 | 16 | 13 | 11 | 19 +58% | 26 +63% |
| Net profit | 5 | 6 | 5 | 5 | 10 +100% | 11 +83% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
